Group 1: Financial Performance - In 2024, the company's revenue was CNY 445,864,331.31, a decrease of 32.75% compared to the previous year [2][3] - The net profit attributable to shareholders was CNY 91,547,379.78, down 48.02% year-on-year [2][3] Group 2: Research and Development - In 2024, the company invested CNY 32,937,088.26 in R&D and reported one Chinese invention patent [2] - The company has obtained several drug registration certificates, including for ibuprofen sustained-release capsules and tolvaptan injection [3] Group 3: Future Plans - The company aims to reduce production costs and enhance market competitiveness through technological upgrades [3] - A new R&D center in Wuhan has been established to accelerate the development of a CDMO one-stop service platform [3] Group 4: Shareholder Engagement - The company currently has no plans for share buybacks but will disclose any future plans in accordance with regulations [2] - The company actively engages with investors through online platforms for Q&A sessions [2]

沙湾市市场监督管理局2025年4月药品经营企业日常监督检查公示 | 月20 | 司二十一分店 | 日 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025 | 1.立查立改；2.下达责令 | 新疆颐仁堂医药连 | 赵 | 年3 | 1.甲类非处方药与乙类非处方药混放；2.第三类医疗器械器械销售信息不全；3.该店执业药师 | 整改通知书（沙市监责 | 锁沙湾市第三百六 | 怀 | 10 | | | 月24 | （质量负责人）不在岗；4.部分药品未分区摆放。 | 改【2025】55号）要求 | 十店 | 朝 | 日 | 限期改正。 | | | | | | 2025 | 吴 | 年3 | 随机抽取诺和针（国械注进20173151271）随货同行单及相关资质，销售记录，三类医疗器械 | 11 沙湾市品康颐仁堂 | 兴 | 立查立改 | | | | | | 月25 | 医药有限公司 | 销售记录不完整。 | 山 | 日 | | | | | | | | 2025 | 赵 | 年3 | 1.拆 ...